A Phase 1 interventional study of VK2735 Drug and Placebo in Obese Adults, sponsored by Viking Therapeutics, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Viking Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 998 studies in Weight Loss with a site in United States — 117 open to participants now, 172 under way, 8 of them phase 3. Weight Loss · United States.
Among the 998 studies in Weight Loss with a site in United States, this one is the 149th largest by planned enrollment of the 915 interventional ones that give a count, is one of 55 that started in 2025, is one of 35 in phase 1, reaches primary completion later than 72 of the 171 other live ones, and was the 987th registered.
1,818 studies on the registry are indexed under Weight Loss; 296 are open to participants now.
Browse Weight Loss studies →117 of the 998 studies in Weight Loss with a site in United States are open now. Recruiting first, the newest first:
Viking Therapeutics, Inc. · Sites in United States
Ages 18+
Viking Therapeutics, Inc. · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 6+
Morehouse School of Medicine · Sites in United States
Ages 12+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 199 Weight Loss studies recruiting now, 73 (37%) set no upper age limit and 109 (55%) stop at 75 or younger; 21 take children under 18; 57 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
998 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 106 · Phase 3 40 · Phase 4 33
First in 1996; this study’s year is marked. 55 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 270 is above the median of 80 across 1,564 interventional studies indexed under Weight Loss.
Median enrollment 72 across the 915 interventional studies, 99 across the 76 observational. Of the 769 that completed or were terminated, 231 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 998 have an industry lead sponsor. The 10 most frequent:
Viking Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
Viking Therapeutics, Inc. has 9 studies filed under Weight Loss — fewer than ten, so there is no comparison to draw.
58 of the studies in Weight Loss with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07298915Phase 3University of VirginiaThe Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) | 2026-12 |
| NCT07223242Phase 3University of Texas Southwestern Medical CenterTailored Exercise Training Study Among Adults With HFpEF | 2026-12-30 |
| NCT07104383Phase 3Viking Therapeutics, Inc.VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | 2027-07-01 |
| NCT07104500Phase 3Viking Therapeutics, Inc.VK2735 for Weight Management Phase 3 | 2027-07-01 |
| NCT07560579Million Marker Wellness, Inc.Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity | 2026-11 |
Add all 58 to your calendar (.ics) → With an account.
Among the 998 studies in Weight Loss with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.
Approximately 270 participants will be enrolled across two study parts: Part A and Part B. A total of 18 treatment groups are planned. Part A contains Groups 1 to 12, and Part B contains Groups 13 to 18. Part A will be completed prior to the enrollment of Part B.
Participants in Part A will be randomized equally across 12 treatment arms to receive one of 11 VK2735 dose regimens or a matching placebo regimen. Participants in Part B will be randomized equally across 6 treatment arms to receive one of four VK2735 dose regimens or matching placebo regimen. Each study part is comprised of treatment periods 1 and 2, lasting 21 weeks and 12 weeks, respectively. Study participants may receive a different dosing frequency and/or route of administration between the two periods.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo Subcutaneously (SC) weekly
Drug: Placebo
VK2735 subcutaneously weekly followed by Placebo subcutaneously weekly
Drug: VK2735 Drug · Drug: Placebo
VK2735 subcutaneously weekly followed by VK2735 subcutaneously weekly
Drug: VK2735 Drug
VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week
Drug: VK2735 Drug
VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly
Drug: VK2735 Drug
VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly
Drug: VK2735 Drug
VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly
Drug: VK2735 Drug
VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly
Drug: VK2735 Drug
VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly
Drug: VK2735 Drug
VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week
Drug: VK2735 Drug
VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week
Drug: VK2735 Drug
VK2735 subcutaneously weekly followed by Placebo subcutaneously weekly
Drug: VK2735 Drug · Drug: Placebo
VK2735 subcutaneously weekly followed by VK2735 orally once daily
Drug: VK2735 Drug
VK2735 subcutaneously weekly followed by VK2735 orally once daily
Drug: VK2735 Drug
VK2735 subcutaneously weekly followed by VK2735 orally once daily
Drug: VK2735 Drug
VK2735 subcutaneously weekly followed by Placebo orally once weekly
Drug: VK2735 Drug · Drug: Placebo
VK2735 subcutaneously weekly followed by Placebo orally once daily
Drug: VK2735 Drug · Drug: Placebo
VK2735 subcutaneously weekly followed by VK2735 orally weekly
Drug: VK2735 Drug
SC or oral once daily, once weekly, every other week, or monthly
SC or oral once daily or once weekly
Evaluate the Safety and Tolerability VK2735
-Incidence of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)
Time frame: 33 weeks
Evaluate the Pharmacokinetic profile of VK23735
Pharmacokinetic profile of SC VK2735 by measuring peak plasma concentration (Cmax) after weekly, every other week, or monthly administration; Pharmacokinetic profile of oral VK2735 by measuring peak plasma concentration (Cmax) after daily or weekly administration
Time frame: 38 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.
Of 24 phase 1 interventional studies under Weight Loss, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's planned 18 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VK2735